SecBot SecBot
SECBOTREPLAY Home › Report › TLX

TLX · Telix announced peer-reviewed publication of ProstACT SELECT Phase 1…

Telix Pharmaceuticals Limited · PRESS-RELEASE filed Jul 21, 2026 at 17:00 ET

At the news

BULLISHIMPACT 5/10

PRESS-RELEASE filed Jul 21, 2026 at 17:00 ET

Telix announced peer-reviewed publication of ProstACT SELECT Phase 1 results in Cancers, confirming that 68Ga-PSMA-PET imaging can select patients for TLX591-Tx therapy. The data show a median radiographic progression-free survival of 8.8 months in evaluable patients, a manageable safety profile, and prolonged tumor retention. This is a positive scientific validation for TLX591-Tx's patient-selection strategy and supports the ongoing Phase 3 ProstACT Global trial, but does not change the binary regulatory or commercial outlook for the asset.

  • ProstACT SELECT Phase 1 results published in peer-reviewed journal Cancers.
  • Median radiographic progression-free survival (rPFS) of 8.8 months reported in evaluable patients.
  • TLX591-Tx demonstrated manageable safety profile and prolonged tumor retention with low salivary gland irradiation.
  • Publication supports patient-selection strategy for ongoing Phase 3 ProstACT Global trial in mCRPC.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access